ZYFLO CR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
May 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYFLO CR is an extended-release oral tablet approved in 2007 as an NDA product by Chiesi. The specific indication, mechanism of action, and pharmacologic class are not publicly disclosed in available data. This product represents a mature, oral small-molecule therapeutic in the US market.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely in transition mode, focusing on lifecycle extension strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZYFLO CR currently shows zero linked job openings, reflecting its mature LOE-approaching status. Career opportunities on this product are likely limited to defense roles (sales, account management, customer service) rather than growth or development positions.
Company
Worked on ZYFLO CR at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.